Navigation Links
Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Date:5/20/2013

LAVAL, Quebec, May 20, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced members of its senior management team will make a presentation at the 34th Annual Goldman Sachs Healthcare Conference on Tuesday, June 11, 2013 at 9:20 a.m. PT. The conference will be held at the Terranea Resort in Los Angeles, CA.

A live webcast and audio archive of the presentation will be available on the company's Web site at www.valeant.com. Click on Investor Relations, and then the link to Events and Presentations. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
2. Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders
3. Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal
4. Valeant Pharmaceuticals Provides Efinconazole Update
5. Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results
6. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
7. Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.
8. American Skin Association Announces New Member Of The Board J. Michael Pearson And New Education Council Member Ryan Weldon Of Valeant Pharmaceuticals International, Inc.
9. Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.
10. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.
11. Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):